Cardiac Biomarkers Market Size, Share, Trends, Growth Outlook

Cardiac Biomarkers Market is estimated to increase at a growth rate of 13.9% CAGR over the forecast period from 2024 to 2030.

 

The Cardiac Biomarkers Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others), By End user (Laboratory Testing, Point of Care Testing).

 

An Introduction to Cardiac Biomarkers Market in 2024

The cardiac biomarkers market in 2024 addresses the demand for diagnostic tests used to assess heart function, diagnose cardiovascular diseases, and evaluate patient risk for adverse cardiac events. Cardiac biomarkers are proteins, enzymes, or genetic markers released into the bloodstream in response to myocardial injury, ischemia, or inflammation, providing valuable information on cardiac health and disease status. Biomarkers such as troponin, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP) are commonly measured to aid in the diagnosis of acute coronary syndrome, heart failure, and other cardiovascular conditions. Market growth is driven by factors such as the increasing prevalence of cardiovascular diseases, the need for early detection and risk stratification, and technological advancements enabling rapid and sensitive biomarker testing. Collaboration between diagnostic companies, cardiologists, and clinical laboratories drives innovation in cardiac biomarker assays and point-of-care testing devices, supporting improved cardiovascular care and patient outcomes.

 

Cardiac Biomarkers Market Trend: Rising Incidence of Cardiovascular Diseases

A prominent trend in the Cardiac Biomarkers market is the escalating incidence of cardiovascular diseases (CVDs) globally. Factors such as sedentary lifestyles, unhealthy dietary habits, and aging populations contribute to the increasing prevalence of CVDs, including heart attacks, heart failure, and strokes. As a result, there is a growing demand for accurate and reliable cardiac biomarker testing to aid in early diagnosis, risk stratification, and monitoring of cardiovascular conditions.

Cardiac Biomarkers Market Driver: Growing Emphasis on Preventive Healthcare

A key driver for the Cardiac Biomarkers market is the growing emphasis on preventive healthcare strategies aimed at reducing the burden of cardiovascular diseases. Healthcare systems and policymakers worldwide are increasingly focusing on proactive measures such as screening programs, health education initiatives, and early intervention strategies to prevent the onset and progression of CVDs. Cardiac biomarker testing plays a vital role in these efforts by enabling healthcare providers to identify individuals at high risk of cardiovascular events and implement timely interventions to mitigate risks and improve patient outcomes.

Cardiac Biomarkers Market Opportunity: Technological Advancements in Biomarker Assays

One potential opportunity in the Cardiac Biomarkers market lies in the continued advancement of technologies for biomarker assays. There is a growing need for innovative biomarker testing platforms that offer enhanced sensitivity, specificity, and multiplexing capabilities to improve diagnostic accuracy and prognostic value. Opportunities exist for companies to develop novel biomarker assays using cutting-edge techniques such as next-generation sequencing, mass spectrometry, and microfluidics, which can provide clinicians with deeper insights into cardiovascular health and disease progression. By investing in research and development, companies can capitalize on the growing demand for advanced biomarker testing solutions and gain a competitive edge in the market.

 

Cardiac Biomarkers Market Segmentation

By Type

Troponin

CK-MB

Myoglobin

BNP and NT-proBNP

Others

By Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End use

Laboratory Testing

Point of Care Testing

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Cardiac Biomarkers Market Companies

Abbott

BIOMÉRIEUX

Bio-Rad Laboratories Inc

Creative Diagnostics

Danaher

F. Hoffmann-La Roche Ltd

Life Diagnostics

Quidel Corp

Randox Laboratories Ltd

Siemens Healthcare GmbH

 

Reasons to Buy the Cardiac Biomarkers Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions

• Gain access to detailed insights on the Cardiac Biomarkers Market, encompassing current market size, growth trends, and forecasts till 2030.

• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities

• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends

• Identify lucrative investment avenues and expansion opportunities within the Cardiac Biomarkers Market industry, guided by robust, data-backed analysis.

• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics

• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain

• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics

• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

 

1 Introduction to 2024 Cardiac Biomarkers Market

1.1 Market Overview

1.2 Quick Facts

1.3 Scope/Objective of the Study

1.4 Market Definition

1.5 Countries and Regions Analyzed

1.6 Units, Currency, and Conversions

1.7 Industry Value Chain

 

2 Research Methodology

2.1 Market Size Estimation

2.2 Sources and Research Methodology

2.3 Data Triangulation

2.4 Assumptions and Limitations

 

3 Executive Summary

3.1 Global Cardiac Biomarkers Market Size Outlook, $ Million, 2021 to 2030

3.2 Cardiac Biomarkers Market Outlook By Type, $ Million, 2021 to 2030

3.3 Cardiac Biomarkers Market Outlook By Product, $ Million, 2021 to 2030

3.4 Cardiac Biomarkers Market Outlook By Application, $ Million, 2021 to 2030

3.5 Cardiac Biomarkers Market Outlook by Key Countries, $ Million, 2021 to 2030

 

4 Market Dynamics

4.1 Key Driving Forces of Cardiac Biomarkers Market Industry

4.2 Key Market Trends in Cardiac Biomarkers Market Industry

4.3 Potential Opportunities in Cardiac Biomarkers Market Industry

4.4 Key Challenges in Cardiac Biomarkers Market Industry

 

5 Market Factor Analysis

5.1 Competitive Landscape

5.1.1 Global Cardiac Biomarkers Market Share by Company (%), 2023

5.1.2 Product Offerings by Company

5.2 Porter’s Five Forces Analysis

 

6 Growth Outlook Across Scenarios

6.1 Growth Analysis-Case Scenario Definitions

6.2 Low Growth Scenario Forecasts

6.3 Reference Growth Scenario Forecasts

6.4 High Growth Scenario Forecasts

 

7 Global Cardiac Biomarkers Market Outlook By Segments

7.1 Cardiac Biomarkers Market Outlook by Segments

By Type

Troponin

CK-MB

Myoglobin

BNP and NT-proBNP

Others

By Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End use

Laboratory Testing

Point of Care Testing

 

8 North America Cardiac Biomarkers Market Analysis And Outlook To 2030

8.1 Introduction to North America Cardiac Biomarkers Markets in 2024

8.2 North America Cardiac Biomarkers Market Size Outlook by Country, 2021-2030

8.2.1 United States

8.2.2 Canada

8.2.3 Mexico

8.3 North America Cardiac Biomarkers Market size Outlook by Segments, 2021-2030

By Type

Troponin

CK-MB

Myoglobin

BNP and NT-proBNP

Others

By Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End use

Laboratory Testing

Point of Care Testing

 

9 Europe Cardiac Biomarkers Market Analysis And Outlook To 2030

9.1 Introduction to Europe Cardiac Biomarkers Markets in 2024

9.2 Europe Cardiac Biomarkers Market Size Outlook by Country, 2021-2030

9.2.1 Germany

9.2.2 France

9.2.3 Spain

9.2.4 United Kingdom

9.2.4 Italy

9.2.5 Russia

9.2.6 Norway

9.2.7 Rest of Europe

9.3 Europe Cardiac Biomarkers Market Size Outlook By Segments, 2021-2030

By Type

Troponin

CK-MB

Myoglobin

BNP and NT-proBNP

Others

By Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End use

Laboratory Testing

Point of Care Testing

 

10 Asia Pacific Cardiac Biomarkers Market Analysis And Outlook To 2030

10.1 Introduction to Asia Pacific Cardiac Biomarkers Markets in 2024

10.2 Asia Pacific Cardiac Biomarkers Market Size Outlook by Country, 2021-2030

10.2.1 China

10.2.2 India

10.2.3 Japan

10.2.4 South Korea

10.2.5 Indonesia

10.2.6 Malaysia

10.2.7 Australia

10.2.8 Rest of Asia Pacific

10.3 Asia Pacific Cardiac Biomarkers Market size Outlook by Segments, 2021-2030

By Type

Troponin

CK-MB

Myoglobin

BNP and NT-proBNP

Others

By Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End use

Laboratory Testing

Point of Care Testing

 

11 South America Cardiac Biomarkers Market Analysis And Outlook To 2030

11.1 Introduction to South America Cardiac Biomarkers Markets in 2024

11.2 South America Cardiac Biomarkers Market Size Outlook by Country, 2021-2030

11.2.1 Brazil

11.2.2 Argentina

11.2.3 Rest of South America

11.3 South America Cardiac Biomarkers Market size Outlook by Segments, 2021-2030

By Type

Troponin

CK-MB

Myoglobin

BNP and NT-proBNP

Others

By Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End use

Laboratory Testing

Point of Care Testing

 

12 Middle East And Africa Cardiac Biomarkers Market Analysis And Outlook To 2030

12.1 Introduction to Middle East and Africa Cardiac Biomarkers Markets in 2024

12.2 Middle East and Africa Cardiac Biomarkers Market Size Outlook by Country, 2021-2030

12.2.1 Saudi Arabia

12.2.2 UAE

12.2.3 Oman

12.2.4 Rest of Middle East

12.2.5 Egypt

12.2.6 Nigeria

12.2.7 South Africa

12.2.8 Rest of Africa

12.3 Middle East and Africa Cardiac Biomarkers Market size Outlook by Segments, 2021-2030

By Type

Troponin

CK-MB

Myoglobin

BNP and NT-proBNP

Others

By Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End use

Laboratory Testing

Point of Care Testing

 

13 Company Profiles

13.1  Company Snapshot

13.2 SWOT Profiles

13.3 Products and Services

13.4 Recent Developments

13.5 Financial Profile

List of Companies

Abbott

BIOMÉRIEUX

Bio-Rad Laboratories Inc

Creative Diagnostics

Danaher

F. Hoffmann-La Roche Ltd

Life Diagnostics

Quidel Corp

Randox Laboratories Ltd

Siemens Healthcare GmbH

 

14 Appendix

14.1 Customization Offerings

14.2 Subscription Services

14.3 Related Reports

14.4 Publisher Expertise

Cardiac Biomarkers Market Segmentation

By Type

Troponin

CK-MB

Myoglobin

BNP and NT-proBNP

Others

By Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End use

Laboratory Testing

Point of Care Testing

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)